Wei Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Xiao has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Xiaojun Xu
Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
4 shared publications Kuai Yu
Department of Transfusion Medicine, Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
3 shared publicationsMei Xie
Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
3 shared publicationsTiantian Sun
Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
3 shared publicationsYaqun Wang
Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
3 shared publications- Yuanbin Song
Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou City, China
3 shared publications
Latest Publications
- 31 July 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 186
MICA gene modulates immune microenvironment and comorbid mechanisms in diffuse large B-cell lymphoma and primary Sjögren’s syndrome
- 31 July 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 186
MICA gene modulates immune microenvironment and comorbid mechanisms in diffuse large B-cell lymphoma and primary Sjögren’s syndrome
- Open Access
- 18 April 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
The PPTC7/BNIP3/NIX axis induces cGAS/STING-mediated senescence and augments CAR-T efficacy by repressing tumor-intrinsic mitophagy
In multiple myeloma (MM), resistance to B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) treatment continues to limit the
- 18 April 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessThe PPTC7/BNIP3/NIX axis induces cGAS/STING-mediated senescence and augments CAR-T efficacy by repressing tumor-intrinsic mitophagy
In multiple myeloma (MM), resistance to B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) treatment continues to limit the
- Open Access
- 15 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3535
Single-Cell Analysis Highlights Pivotal Role of Eosinophil–Basophil Mast Cell Progenitor-Related Mechanism in Primary Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is an autoimmune disease. Megakaryocyte dysfunction caused by autoimmune response can lead to thrombocytopenia, and the underlying mechanism is still unclear. Single-cell sequencing analysis revealed the heterogeneity of CD34 + HSPCs in bone marrow between ITP patients and healthy groups. Pre-B cell population 1 (pre-B1) showed a significantly lower percentage contribution in ITP groups, and the underlying mechanism involves cell cycle-, cell apoptosis- and cell death-related pathways. The number of eosinophil–basophil mast cell progenitors (EBMPs) is significantly increased in ITP patients and the DEGs of the EBMPs in ITP patients were significantly enriched in immune-related pathways. Further, immunofluorescent staining and Western blot assay highlight C-X-C Motif Chemokine Ligand 8 (CXCL8) and Interferon Regulatory Factor 1 (IRF1) expression were significantly increased in the EBMPs of ITP patients. Furthermore, cell–cell communication analysis identified an impaired LGALS9-CD44 axis between EBMP cells and MkP1 cells in ITP patients, suggesting that targeting the LGALS9-CD44 interaction might hold promise as a therapeutic approach for ITP. Our observations indicate that ITP patients exhibit an elevated proportion of EBMP cells alongside a reduced proportion of pre-B1 cells. CXCL8 and IRF1 are potentially associated with EBMP cell dysfunction and the ITP disease process. Furthermore, the diminished LGALS9-CD44 axis between EBMP and MkP1 cells may contribute to ITP progression, suggesting a direction for future therapeutic investigation.
- 15 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3535
Open AccessSingle-Cell Analysis Highlights Pivotal Role of Eosinophil–Basophil Mast Cell Progenitor-Related Mechanism in Primary Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is an autoimmune disease. Megakaryocyte dysfunction caused by autoimmune response can lead to thrombocytopenia, and the underlying mechanism is still unclear. Single-cell sequencing analysis revealed the heterogeneity of CD34 + HSPCs in bone marrow between ITP patients and healthy groups. Pre-B cell population 1 (pre-B1) showed a significantly lower percentage contribution in ITP groups, and the underlying mechanism involves cell cycle-, cell apoptosis- and cell death-related pathways. The number of eosinophil–basophil mast cell progenitors (EBMPs) is significantly increased in ITP patients and the DEGs of the EBMPs in ITP patients were significantly enriched in immune-related pathways. Further, immunofluorescent staining and Western blot assay highlight C-X-C Motif Chemokine Ligand 8 (CXCL8) and Interferon Regulatory Factor 1 (IRF1) expression were significantly increased in the EBMPs of ITP patients. Furthermore, cell–cell communication analysis identified an impaired LGALS9-CD44 axis between EBMP cells and MkP1 cells in ITP patients, suggesting that targeting the LGALS9-CD44 interaction might hold promise as a therapeutic approach for ITP. Our observations indicate that ITP patients exhibit an elevated proportion of EBMP cells alongside a reduced proportion of pre-B1 cells. CXCL8 and IRF1 are potentially associated with EBMP cell dysfunction and the ITP disease process. Furthermore, the diminished LGALS9-CD44 axis between EBMP and MkP1 cells may contribute to ITP progression, suggesting a direction for future therapeutic investigation.
- 31 March 2026
- Published by Elsevier in Biomaterials
- Vol. 333, 124187
Sustained IL-15 release enhances CAR-T therapy in multiple myeloma via FOXO1 signaling axis activation
- 31 March 2026
- Published by Elsevier in Biomaterials
- Vol. 333, 124187
Sustained IL-15 release enhances CAR-T therapy in multiple myeloma via FOXO1 signaling axis activation
- Open Access
- 21 January 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (2) , 104611
Humanized liver mouse models in preclinical drug development: current status, translation challenges and emerging technologies
- 21 January 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (2) , 104611
Open AccessHumanized liver mouse models in preclinical drug development: current status, translation challenges and emerging technologies